Emerging markets are on the radar for global asset allocation strategies these days on the assumption that these countries will be the main beneficiaries of the vaccine-led global economic recovery. It’s an intriguing narrative and not without merit, but so far the results are mixed, based on looking at a broad-brush proxy for EM stocks.